Pharmacologic Management of Monogenic and Very Early Onset Inflammatory Bowel Diseases

Pharmacologic Management of Monogenic and Very Early Onset Inflammatory Bowel Diseases

Inflammatory bowel disease (IBD) is treated with a variety of immunomodulating and immunosuppressive therapies; however, for the majority of cases, these therapies are not targeted for specific disease phenotypes. Monogenic IBD with causative genetic defect is the exception and represents a disease...

Full description

Bibliographic Details
Main Authors: Anne E. Levine, Dominique Mark, Laila Smith, Hengqi B. Zheng, David L. Suskind
Format: Article
Language:English
Published: MDPI AG 2023-03-01
Series:Pharmaceutics
Subjects:
very early onset inflammatory bowel disease (VEO-IBD)
pharmacotherapy
monogenic IBD
management
Online Access:https://www.mdpi.com/1999-4923/15/3/969

Internet

https://www.mdpi.com/1999-4923/15/3/969

Similar Items